Invesco
STLN

Invesco’s Starling Oncology STLN Stock Holding History

Invesco’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.86M Buy
342,166
+304,947
+819% +$1.28M ﹤0.01% 2619
2026
Q1 		$114K Sell
37,219
-9,793
-21% -$30K ﹤0.01% 3607
2025
Q4 		$167K Buy
47,012
+8,425
+22% +$31.2K ﹤0.01% 3569
2025
Q3 		$135K Sell
38,587
-121
-0.3% -$415 ﹤0.01% 3640
2025
Q2 		$79.4K Buy
+38,708
New +$96.8K ﹤0.01% 3678
2023
Q2 		– Sell
-11,398
Closed -$7.73K – 3947
2023
Q1 		$7.73K Buy
11,398
+241
+2% +$307 ﹤0.01% 3846
2022
Q4 		$18.4K Sell
11,157
-1,485
-12% -$4.17K ﹤0.01% 3976
2022
Q3 		$58K Buy
+12,642
New +$74.3K ﹤0.01% 3903

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Invesco's STLN Position: Q2 2026 in Review

Invesco increased its Starling Oncology (STLN) stake by 819% in Q2 2026, buying an estimated $1.28M and bringing the position to 342,166 shares worth $1.86M. The position accounts for ﹤0.01% of the portfolio, ranked #2619.

Invesco first reported a position in STLN in Q3 2022 and has held it in 8 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Invesco held 342,166 shares of Starling Oncology worth $1.86M as of Q2 2026.
  • Invesco bought 304,947 Starling Oncology shares in Q2 2026, an estimated $1.28M.
  • Starling Oncology made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2619 holding.
  • Invesco first reported a position in Starling Oncology in Q3 2022 and has held it in 8 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.